GENO Stock Overview
Develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr33.80 |
| 52 Week High | kr57.60 |
| 52 Week Low | kr25.65 |
| Beta | 1.47 |
| 1 Month Change | 20.28% |
| 3 Month Change | -21.30% |
| 1 Year Change | -38.55% |
| 3 Year Change | -17.56% |
| 5 Year Change | 92.05% |
| Change since IPO | -68.41% |
Recent News & Updates
This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09
Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18Recent updates
This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate
May 09Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 26Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?
Mar 27How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?
Dec 30Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?
Nov 23
Shareholder Returns
| GENO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 13.8% | 5.4% | 0.4% |
| 1Y | -38.5% | 0.6% | 14.1% |
Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned 1.4% over the past year.
Return vs Market: GENO underperformed the Swedish Market which returned 14% over the past year.
Price Volatility
| GENO volatility | |
|---|---|
| GENO Average Weekly Movement | 9.1% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: GENO's share price has been volatile over the past 3 months.
Volatility Over Time: GENO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 37 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease.
Genovis AB (publ.) Fundamentals Summary
| GENO fundamental statistics | |
|---|---|
| Market cap | kr2.21b |
| Earnings (TTM) | kr30.68m |
| Revenue (TTM) | kr128.42m |
72.1x
P/E Ratio17.2x
P/S RatioIs GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENO income statement (TTM) | |
|---|---|
| Revenue | kr128.42m |
| Cost of Revenue | kr13.63m |
| Gross Profit | kr114.79m |
| Other Expenses | kr84.11m |
| Earnings | kr30.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 89.38% |
| Net Profit Margin | 23.89% |
| Debt/Equity Ratio | 0% |
How did GENO perform over the long term?
See historical performance and comparison